Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Liabilities and Shareholders Equity: 2011-2025

Historic Liabilities and Shareholders Equity for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to $239.3 million.

  • Lifecore Biomedical's Liabilities and Shareholders Equity fell 5.76% to $239.3 million in Q2 2025 from the same period last year, while for May 2025 it was $979.2 million, marking a year-over-year decrease of 1.25%. This contributed to the annual value of $239.3 million for FY2025, which is 5.76% down from last year.
  • Per Lifecore Biomedical's latest filing, its Liabilities and Shareholders Equity stood at $239.3 million for Q2 2025, which was up 0.69% from $237.7 million recorded in Q1 2025.
  • Lifecore Biomedical's Liabilities and Shareholders Equity's 5-year high stood at $506.9 million during Q1 2021, with a 5-year trough of $236.7 million in Q1 2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $246.1 million, with a median of $246.0 million in 2023.
  • In the last 5 years, Lifecore Biomedical's Liabilities and Shareholders Equity spiked by 71.00% in 2021 and then crashed by 45.27% in 2022.
  • Lifecore Biomedical's Liabilities and Shareholders Equity (Quarterly) stood at $421.3 million in 2021, then tumbled by 34.50% to $276.0 million in 2022, then fell by 10.93% to $245.8 million in 2023, then increased by 3.89% to $255.4 million in 2024, then fell by 5.76% to $239.3 million in 2025.
  • Its last three reported values are $239.3 million in Q2 2025, $237.7 million for Q1 2025, and $255.4 million during Q4 2024.